Abstrakt

A systematic review on intravenous lipid emulsion

Poovitha Thangamani*, Kodiarasu, Raima Sabu, Reshma Elizabeth Raju, V. Shangavi

Intravenous lipid emulsion (ILE) therapy is an emerging, but unproven therapy for refractory cardiotoxicity due to lipid-soluble drugs. Its promise was first recognized in a rat model of bupivacaine toxicity. and has gained visibility in the clinical arena after reports of its use for bupivacaine and other drug toxicities. Evidence for ILE in the management of drug-related cardiotoxicity is limited at this time to animal studies and human case reports. Animal models have demonstrated improved survival from drug-induced cardiotoxicity from bupivacaine, clomipramine, propranolol, atenolol, and verapamil when ILE is administered during resuscitative efforts. Human case reports in the literature document recovery from cardiovascular collapse due to poisoning from bupivacaine, ropivacaine, bupropion/lamotrigine, mepivicaine/bupivacaine, and levobupivacaine